Elicio Therapeutics Inc (ELTX)
7.88
+0.37
(+4.93%)
USD |
NASDAQ |
May 31, 16:00
7.90
+0.02
(+0.25%)
After-Hours: 20:00
Elicio Therapeutics Enterprise Value: 69.08M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 69.08M |
| May 30, 2024 | 65.28M |
| May 29, 2024 | 66.41M |
| May 28, 2024 | 70.82M |
| May 24, 2024 | 74.52M |
| May 23, 2024 | 79.04M |
| May 22, 2024 | 79.14M |
| May 21, 2024 | 79.14M |
| May 20, 2024 | 89.41M |
| May 17, 2024 | 91.36M |
| May 16, 2024 | 84.48M |
| May 15, 2024 | 94.96M |
| May 14, 2024 | 93.93M |
| May 13, 2024 | 87.26M |
| May 10, 2024 | 84.79M |
| May 09, 2024 | 85.35M |
| May 08, 2024 | 83.81M |
| May 07, 2024 | 80.74M |
| May 06, 2024 | 80.03M |
| May 03, 2024 | 80.03M |
| May 02, 2024 | 80.23M |
| May 01, 2024 | 78.70M |
| April 30, 2024 | 82.28M |
| April 29, 2024 | 81.25M |
| April 26, 2024 | 80.13M |
| Date | Value |
|---|---|
| April 25, 2024 | 81.25M |
| April 24, 2024 | 82.79M |
| April 23, 2024 | 82.48M |
| April 22, 2024 | 87.80M |
| April 19, 2024 | 74.09M |
| April 18, 2024 | 72.35M |
| April 17, 2024 | 83.30M |
| April 16, 2024 | 86.68M |
| April 15, 2024 | 82.58M |
| April 12, 2024 | 88.93M |
| April 11, 2024 | 89.34M |
| April 10, 2024 | 77.88M |
| April 09, 2024 | 78.08M |
| April 08, 2024 | 76.65M |
| April 05, 2024 | 78.59M |
| April 04, 2024 | 65.00M |
| April 03, 2024 | 63.47M |
| April 02, 2024 | 63.98M |
| April 01, 2024 | 60.91M |
| March 28, 2024 | 64.79M |
| March 27, 2024 | 63.35M |
| March 26, 2024 | 59.68M |
| March 25, 2024 | 57.63M |
| March 22, 2024 | 56.81M |
| March 21, 2024 | 54.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
18.80M
Minimum
Jan 24 2024
152.29M
Maximum
Jun 02 2023
55.80M
Average
52.21M
Median
Mar 19 2024
Enterprise Value Benchmarks
| Immuneering Corp | -30.06M |
| Outlook Therapeutics Inc | 162.76M |
| Amylyx Pharmaceuticals Inc | -256.32M |
| NovaBay Pharmaceuticals Inc | 4.387M |
| Palatin Technologies Inc | 19.03M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.83M |
| Total Expenses (Quarterly) | 10.24M |
| EPS Diluted (Quarterly) | -1.15 |
| Earnings Yield | -73.50% |